Advances in Chronic Kidney Disease
Volume 15, Issue 2 , Pages 186-190 , April 2008

Iron Indices and Vitamin D Receptor Polymorphisms in Hemodialysis Patients

References 

  1. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315
  2. Marco MP, Craver L, Betriu A, et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. 2003;63:S111–S114(suppl 85)
  3. Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in hemodialysis patients. Nephrol Dial Transplant. 2006;21:991–998
  4. Marco MP, Craver L, Betriu A, et al. Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients. Am J Kidney Dis. 2001;4:965–974
  5. Li YC, Qiao G, Uskokovic M, et al. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89:387–392
  6. Aterini S, Salvadori M, Ippolito E, et al. The role of vitamin D receptor gene alleles in the secondary hyperparathyroidism of hemodialysis patients. J Nephrol. 1996;9:201–206Available at: http://www.sin-italy.org/vecchiosito/jnonline/vol9n4/201.htmlAccessed February 21, 2008
  7. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 2003;108:2041–2048
  8. Frankel BJ, Heldt AM, Grodsksy GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209:823–825
  9. Ertürk S, Kutlay S, Karabulut HG, et al. The impact of vitamin D receptor genotype on the management of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:816–823
  10. Uitterlinden AG, Fang Y, Van Meurs JB, et al. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338:143–156
  11. Vigo Gago E, Cadarso-Suarez C, Perez-Fernandez R, et al. Association between vitamin D receptor FokI. Polymorphism and serum parathyroid hormone level in patients with chronic renal failure. J Endocrinol Invest. 2005;28:117–121
  12. Pupim LB, Caglar K, Hakim RM, et al. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int. 2004;66:2054–2060
  13. Coyne D. Iron indices: What do they really mean?. Kidney Int. 2006;69:S4–S8(suppl 101)
  14. Gross C, Krishnan AV, Malloy PJ, et al. The vitamin D receptor gene start codon polymorphism: A functional analysis of FokI variants. J Bone Miner Res. 1998;13:1691–1699
  15. Arai H, Miyamoto KI, Taketani Y, et al. A vitamin D receptor gene polymorphism in the translation initiation codon: Effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res. 1997;12:915–921
  16. Kulah E, Dursun A, Acikgoz S, et al. The relationship of target organ damage and 24-hour ambulatory blood pressure monitoring with vitamin D receptor gene fok-I polymorphism in essential hypertension. Kidney Blood Press Res. 2006;29:344–350
  17. Levin A, Li YC. Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease?. Kidney Int. 2005;68:1973–1981
  18. Andress DL. Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33–43
  19. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–456
  20. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1 alpha-hydroxy vitamin D-3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19:179–184
  21. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol. 2005;16:1115–1125
  22. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823–2828
  23. Makibayashi K, Tatematsu M, Hirata M, et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol. 2001;158:1733–1741
  24. Zhang Z, Yuan W, Sun L, et al. 1,25-Dihydroxyvitamin D-3 targeting of NF-kappa B suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 2007;72:193–201
  25. Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008;73:163–171
  26. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D-3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol. 2004;286:F526–F533

 Supported by grants from Foundation “Cassa di Risparmio di Firenze” and the University of Firenze, Italy.

PII: S1548-5595(08)00014-1

doi: 10.1053/j.ackd.2008.01.013

Advances in Chronic Kidney Disease
Volume 15, Issue 2 , Pages 186-190 , April 2008

Article Tools